Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nomura Kotaro, Watanabe Takuya, Takamori Shinkichi, Hamada Akira, Suda Kenichi, Ito Masaoki, Ohara Shuta, Oiki Hana, Fukami Tomoyo, Muto Satoshi, Katsumata Shinya, Konno Hayato, Hayasaka Kazuki, Toyoda Takahide, Endo Makoto, Takamori Satoshi, Nakatsuka Marina, Tenpaku Hironori, Takegahara Kyoshiro, Matsubara Taichi, Kinoshita Fumihiko, Akamine Takaki, Nakamura Ryuji, Mizuno Kiyomichi, Nakagawa Keisuke, Kaneda Shinji, Okada Satoru, Kosai Keisuke, Notsuda Hirotsugu, Sakane Tadashi, Shinohara Shuichi, Abe Miyuki, Haratake Naoki, Tane Shinya, Hanawa Ryutaro, Tarukawa Tomohito, Namba Kei, Toda Michihito, Kawaguchi Teruhisa, Takada Kazuki, Minegishi Kentaro, Kurihara Nobuyasu, Iguchi Takahumi, Aokage Keiju, Tsutani Yasuhiro, Tsuboi Masahiro, Soh Junichi, Shimokawa Mototsugu, Ohde Yasuhisa
Аннотация
METHODS: We conducted a multicenter retrospective study using real-world data of patients with resectable stage II or III NSCLC treated with neoadjuvant chemoimmunotherapy with nivolumab between March 2023 and July 2024 at 29 Japanese institutions. The safety, AE profiles, and risk factors for grade ≥3 AEs were evaluated.
RESULTS: A total of 126 patients were analyzed. In the neoadjuvant phase, grade ≥3 treatment-related AEs and immune-related AEs (irAEs) occurred in 36 (28.6%) and 12 (9.5%) patients, respectively. One patient (0.8%) died of a neoadjuvant treatment-related cytokine storm AE and subsequent multiorgan failure. Definitive surgery after neoadjuvant treatment was performed in 114 patients (90.5%), with only 1 death within 90 days of surgery. Half of endocrine-related irAEs occurred in the postoperative phase. Among the demographic characteristics, a history of coronary artery disease was a significant risk factor for grade ≥3 treatment-related AEs (odds ratio, 16.556; 95% CI, 1.698-161.479; P = .016) and irAEs (odds ratio, 10.196; 95% CI, 1.193-87.166;, P = .034).
CONCLUSIONS: Real-world data from the era of neoadjuvant chemoimmunotherapy showed feasibility consistent with the results of randomized controlled trials. The incidence of grade ≥3 AEs was not particularly high but was clinically significant, and a history of coronary artery disease may be a predictor.